The phase I/II clinical trial (NCT03395210) by Kuter et al. 2022 [19] included highly refractory ITP patients with a median of four lines of prior treatments (glucocorticoid, rituximab, TPO, IVIG, fostamatinib, splenectomy). The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.